Episodes

  • Part II: Early Alzheimer Disease Detection through a Davos Alzheimer's Collaborative Initiative: Lessons from Real-World Implementation

    Part II: Early Alzheimer Disease Detection through a Davos Alzheimer's Collaborative Initiative: Lessons from Real-World Implementation
    Jun 12 2026
    This episode explores the real-world implementation of the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) US Early Detection Program at Virtua Health, examining outcomes in identifying cognitive impairment, streamlining referrals, and supporting efficient use of clinical resources. Elyse Perweiler, RN, MPP, Professor, Rowan–Virtua School of Osteopathic Medicine, Stratford, NJ, and Tim MacLeod, PhD, Executive Director, Healthcare System Preparedness Program, DAC, Toronto, Ontario, Canada, return for part 2 of this 3 part series.
    Show More Show Less
    19 mins
  • Part I: Early Alzheimer Disease Detection with the DAC-SP Blueprint Program: Overview of a Scalable Health System Approach

    Part I: Early Alzheimer Disease Detection with the DAC-SP Blueprint Program: Overview of a Scalable Health System Approach
    Feb 12 2026
    Elyse Perweiler, RN, MPP, Professor, Rowan–Virtua School of Osteopathic Medicine, Stratford, NJ, and Tim MacLeod, PhD, Program Director, Healthcare System Preparedness Program, Davos Alzheimer’s Collaborative (DAC), Toronto, Ontario, Canada, examine how health systems can operationalize early cognitive screening to better prepare patients for specialty evaluation. Learn how standardized workflows, digital cognitive tools, and primary care–neurology collaboration can enhance diagnostic efficiency and access to Alzheimer disease care.
    Show More Show Less
    18 mins
  • Detecting Multiple Sclerosis Earlier: PRLs and the Evolving McDonald Diagnostic Criteria

    Detecting Multiple Sclerosis Earlier: PRLs and the Evolving McDonald Diagnostic Criteria
    Dec 15 2025
    This episode explores new evidence showing that paramagnetic rim lesions (PRLs) are highly prevalent early in multiple sclerosis (MS) and can differentiate MS from mimics with striking accuracy. Dr. Daniel Ontaneda, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, and Dr. Pascal Sati, Cedars-Sinai Medical Center, Los Angeles, CA, discuss how PRLs, paired with optimized susceptibility-based MRI, are reshaping diagnostic confidence and informing the latest revisions to the McDonald criteria.
    Show More Show Less
    30 mins
  • Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

    Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies
    Dec 3 2025
    Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance of comprehensive molecular testing, the World Health Organization classification of tumors of the central nervous system, and newly available therapies.
    Show More Show Less
    14 mins
  • Maturing with Migraine: Practical Guidelines for Transitioning Adolescent Migraine and Headache Patients into Adult Practice

    Maturing with Migraine: Practical Guidelines for Transitioning Adolescent Migraine and Headache Patients into Adult Practice
    Dec 2 2025
    Hope O’Brien, MD, MBA, FAHS, FAAN, Founder and CEO of the Headache Center of Hope, Cincinnati, OH, discusses challenges and considerations for adult headache neurologists who are onboarding adolescent patients as they transition from pediatric practice. Dr. O’Brien highlights a framework with strategies for a seamless transition, while noting best practices for promoting patient autonomy and mental wellbeing.
    Show More Show Less
    24 mins
  • Advances in ALS: New Targets, Trials, and Care Strategies

    Advances in ALS: New Targets, Trials, and Care Strategies
    Oct 27 2025
    Merit Cudkowicz, MD, Julieanne Professor of Neurology, Harvard Medical School, Boston, MA, discusses the evolving landscape of treatment for ALS, including FDA-approved disease-modifying therapies, the importance of genetic testing, the emergence of gene therapies, and the promising clinical trial pipeline targeting genetic and sporadic forms of ALS.
    Show More Show Less
    15 mins
  • Cerebrovascular Inflammatory Conditions: Diagnostic Challenges and Treatment Considerations

    Cerebrovascular Inflammatory Conditions: Diagnostic Challenges and Treatment Considerations
    Oct 22 2025
    Abbas Kharal, MD, MPH, Neurologist at Cleveland Clinic Neurological Institute, Cleveland, OH, provides a review of cerebrovascular inflammatory conditions, with an emphasis on diagnostic challenges, the evolving treatment landscape, and the use of imaging and clinical responses to assist clinicians with early detection and differentiation of these conditions.
    Show More Show Less
    19 mins
  • The Evolving Therapeutic Landscape for Parkinson Disease

    The Evolving Therapeutic Landscape for Parkinson Disease
    Jun 6 2025
    Mark Stacy, MD, William E. Murray Professor of Neurology, Medical University of South Carolina, Charleston, SC, discusses the evolving therapeutic landscape for Parkinson disease, highlighting promising advances in neuroprotective therapies, biomarkers, personalized medicine, and innovative clinical trial designs that aim to improve both treatment outcomes and accessibility.
    Show More Show Less
    21 mins